Clinical Trial Update: A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating the oral agent BRX011 for geographic atrophy due to age-related macular degeneration; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Geographic Atrophy

Drugs mentioned

• BRX011 (BRX011)

Snippet

Sponsor: Biojiva LLC | Conditions: Geographic Atrophy | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING